HeraMED CEO David Groberman talks about the company’s progress
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
The Mayo Clinic has been established for more than 150 years, and employs more than 4500 physicians and scientists along with 54,000 allied health staff across 19 hospitals in five US states. It has been ranked No 1 hospital in the world for three years in a row by US news and world reports.
It is also an important partner to Medical technology group HeraMED Limited (ASX:HMD), which has gone from strength to strength since listing on the ASX in December 2018, excelling in the area of product development and distribution, but also forging alliances with other global, high profile medical institutions.
Recently, HeraMED CEO David Groberman sat down with Investor Stream to discuss the Mayo Clinic relationship, recent FDA clearance for HeraBEAT and how it is attempting to build acknowledgement and appreciation amongst medical professionals.
HeraMED has had a strong month of newsflow, firstly with its 510(k) application (K191110) for the company’s HeraBEAT US foetal ultrasonic heart rate monitor (HeraBEAT US) cleared by the US Food and Drug Administration (FDA).
Secondly, with the company announcing that it has entered into an agreement with leading midwife service provider, Kinderheldin GmbH.
Kinderheldin (www.kinderheldin.de) is a leading midwife service provider based in Berlin, which has developed a web based, online platform that offers expecting parents access to large number of midwives through online chat services or telephones.
HeraMED chief executive and co-founder David Groberman said, “This agreement provides HeraMED with a significant differentiator and competitive advantage.
‘’Having a midwifery service that expecting mothers and new parents can access as part of our service offering puts the company leagues ahead as it pushes further into telehealth and connected care.
“Kinderheldin is a tremendous partner for HeraMED as it boasts strong relationships with some of Germany’s oldest and largest insurance companies and hospital groups.
“We look forward to progressing discussions with the top-tier organisations in their network with the aim to implement HeraBEAT and potentially HeraCARE more broadly.”
We expect plenty more news to flow from the company over the coming months and will keep you abreast of all developments.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.